Will the big guys win? Following FDA approval of Micera for anemic patients in the United States, Roche is still held back by Amgen's patent infringement case.
As one of the largest domestic biotech companies, Amgen currently dominates the anemia market with Aranesp and Epogen. A court decided in favor of Amgen last month, and they are filing an injunction in Boston today to prevent Roche from marketing Micera in the U.S. According to the November 15, 2007 online edition of the NJ Star Ledger, the injunction is a foregone conclusion.
This surely comes as a crushing blow to Roche, especially having cleared the significant hurdle of FDA approval.
It's nice to see the little guy win when it happens, but maybe what this story really tells us is—when it comes to medical patents (or any patent for that matter) size doesn't matter. But, being first does.